HARMONY: Better care of patients with hematologic malignancies kicked off!

Logo Harmony Horizontal FullText

“Combining data available from clinical trials as well as real world patients allows us to do more advanced analyses on possible treatment options that could be effective for individual patient or categories of patients”, said Jesús María Hernandez Rivas, Project Coordinator of HARMONY and Professor in Hematology at the University Medical Hospital of Salamanca, Spain.

To showcase the impact of Big Data analyses on possible treatment options, a ‘proof of principle’ study on AML was presented by Dr Lars Bullinger from the University of Ulm, Germany. This inspired the discussion amongst participants on how to apply these analyses in other disease areas.

“Big Data doesn’t mean collecting only large quantities. The quality of the data is much more important. Therefore HARMONY is open to associate partners that can provide high quality data”, Professor Guillermo Sanz, Co-coordinator of HARMONY and Professor in Hematology at the University Medical Hospital of Valencia, Spain explained.

During the meeting concrete action plans for the first of this 5-year project were discussed on e.g. the involvement of the patient community, the collection of data, the construction of the Big Data platform, the legal and ethical framework that has to be taken into account, with the goal to rapidly increase patient access.

“With 51 partners including 7 pharmaceutical companies and over 60 associated partners it is important to have a common understanding about the tasks and roles of each and everyone in the project”, said Pam Bacon from Celgene and member of the HARMONY Executive Committee and EPFIA co-lead.“And that is what we discussed in Salamanca during the breakout sessions of the 8 HARMONY Work Packages. A Paradigm shift towards value is needed. The starting point is to focus on improving patient outcomes and drive healthcare efficiency”, Tay Salimullah from Novartis explained, and member of the HARMONY Executive Committee and EFPIA co-lead.

Contact information: Harmonyoffice@ibsal.es | Download full release in PDF



The Innovative Medicines Initiative (IMI) is Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients. IMI supports collaborative research projects and builds networks of industrial and academic experts in order to boost pharmaceutical innovation in Europe. IMI is a joint undertaking between the European Union and the pharmaceutical industry association EFPIA.



It should be made clear in the text and layout that the communication reflects the author's view and that neither IMI nor the European Union, EFPIA, or any Associated Partners are responsible for any use that may be made of the information contained therein.


Last Updated on Thursday 05 October 2017.